<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6265">
  <stage>Registered</stage>
  <submitdate>22/10/2015</submitdate>
  <approvaldate>22/10/2015</approvaldate>
  <nctid>NCT02624869</nctid>
  <trial_identification>
    <studytitle>Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).</studytitle>
    <scientifictitle>Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)</scientifictitle>
    <utrn />
    <trialacronym>HAUSER-OLE</trialacronym>
    <secondaryid>2015-002276-25</secondaryid>
    <secondaryid>20120124</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Familial Hypercholesterolemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - evolocumab (AMG 145)

Experimental: evolocumab (AMG 145) - Single arm all subjects receive evolocumab (AMG 145) every 4 weeks (QM)


Other interventions: evolocumab (AMG 145)
Administered by subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with treatment-related Adverse Events as assessed by CTCAE V4.0</outcome>
      <timepoint>80 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in non-HDL-C (non high density lipoprotein cholesterol)</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in apoliprotein-b (ApoB)</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline total cholesterol/HDL-C ratio - The change in total cholesterol/HDL-C ratio from baseline at week 80</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline ApoB/ApoA1 ratio - The change in ApoB/ApoA1 ratio from baseline at week 80</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in LDL-C</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in steroid hormones - FSH, LH, ACTH, DHEA-S, cortisol, estradiol/testosterone [females/males, respectively]</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Carotid intima-media thickness (cIMT) at week 80</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject incidence of abnormal muscle enzyme levels</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject incidence of abnormal liver enzyme levels</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in height</outcome>
      <timepoint>Week 24, 48 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in weight.</outcome>
      <timepoint>Week 24, 48 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in pubertal development - Tanner Staging</outcome>
      <timepoint>Week 24, 48 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with abnormal neurological examination findings - The neurologic examination will include assessments of motor, sensory, reflexes, coordination and gait.</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline score in the components of the Cogstate battery (cognitive function assessments) - The Cogstate battery will include the following tests: Groton Maze Learning Task (GMLT; Executive Function); One Card Learning Test (OCL; Visual Memory); Identification Test (IDN; Attention/Vigilance); Detection Test (DET; Psychomotor Speed)</outcome>
      <timepoint>Week 24, 48, and 80</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with HeFH:

        -Completed Study 20120123 while still on assigned investigational product and did not
        experience a treatment-related serious adverse event

        Subjects with HoFH:

          -  Male or female, = 10 to = 17 years of age at time of enrollment

          -  Diagnosis of HoFH

          -  On a low-fat diet and receiving background lipid-lowering therapy

          -  Lipid-lowering therapy unchanged for = 4 weeks prior to LDL-C screening; fibrates must
             be stable for at least 6 weeks prior to screening.

          -  Fasting LDL-C at screening = 130 mg/dL (3.4 mmol/L)

          -  Fasting triglycerides = 400 mg/dL (4.5 mmol/L)</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>All Subjects

        -Currently receiving treatment in another investigational device or drug study, or less
        than 30 days since ending treament on another investigational device or drug study(s);
        except Study 20120123

        Subjects with HoFH:

          -  Moderate to severe renal dysfunction

          -  Active liver disease or hepatic dysfunction,

          -  CK &gt; 3 times the ULN at screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>10/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>115</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Research Site - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Feldkirch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Svitavy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Reinach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab (AMG 145)
      when added to standard of care in pediatric subjects 10 to 17 years of age with HeFH or HoFH.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02624869</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>